Effect of various pyrimidines possessing the 1-[(2-hydroxy-1- (hydroxymethyl)ethoxy)methyl] moiety, able to mimic natural 2′- deoxyribose, on wild-type and mutant hepatitis B virus replication

Journal of Medicinal Chemistry

Volumn 49, Issue 12, 2006, Pages 3693-3700

  Kumar, Rakesh ^a   Semaine, Wassila ^a   Johar, Monika ^a   Tyrrell, D Lorne J ^a   Agrawal, Babita ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

1 [[2 HYDROXY 1 (HYDROXYMETHYL)ETHOXY]METHYL] 5 FLUOROCYTOSINE; 2 DEOXYRIBOSE; 5 (2 BROMOVINYL) 1 [[2 HYDROXY 1 (HYDROXYMETHYL)ETHOXY]METHYL]URACIL; 5 BROMO 6 METHYL 1 [[2 HYDROXY 1 (HYDROXYMETHYL)ETHOXY]METHYL]URACIL; 5 CHLORO 1 [[2 HYDROXY 1 (HYDROXYMETHYL)ETHOXY]METHYL]URACIL; ABACAVIR; BROMINE DERIVATIVE; CHLORINE DERIVATIVE; FLUCYTOSINE; GANCICLOVIR; HALOGEN; HETEROCYCLIC COMPOUND; HYDROXYL GROUP; LAMIVUDINE; METHYL GROUP; PYRIMIDINE DERIVATIVE; PYRIMIDINE NUCLEOSIDE DERIVATIVE; UNCLASSIFIED DRUG; URACIL DERIVATIVE; VINYL DERIVATIVE; VIRUS DNA;

ANTIVIRAL ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CHRONIC LIVER DISEASE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; MOLECULAR SIZE; NONHUMAN; REBOUND; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SARS CORONAVIRUS; STRUCTURE ACTIVITY RELATION; VERO CELL; VIRUS MUTANT; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE; WEST NILE FLAVIVIRUS; WILD TYPE;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CELL LINE, TUMOR; CERCOPITHECUS AETHIOPS; DEOXYRIBOSE; DRUG RESISTANCE, VIRAL; DUCKS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MOLECULAR MIMICRY; MUTATION; PYRIMIDINE NUCLEOSIDES; STRUCTURE-ACTIVITY RELATIONSHIP; VIRUS REPLICATION;

EID: 33745134688     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm060102l     Document Type: Article

References (60)

1. Margolis, H. S.; Alter, M. J.; Hadler, S. C. Hepatitis B: Evolving Epidemiology and Implications for Control. Semin. Liver Dis. 1991, 11, 84-92.
2. Maddrey, W. C. Hepatitis B-An Important Public Health Issue. Clin. Lab. 2001, 47, 51-55.
3. Lok, A. S. Hepatitis B Infection: Pathogenesis and Management. J. Hepatol. 2000, 32 (Suppl. 1), 89-97.
4. Perrillo, R. P.; Schiff, E. R.; Davis, G. L.; Bodenheimer, H. C.; Lindsay, K.; Payne, J.; Dienstag, J. L.; O'Brien, C.; Tamburro, C.; Jacobson, I. M. A Randomized, Control led Trial of Interferon Alfa-2b Alone and After Prednisone Withdrawal for the Treatment of Chronic Hepatitis B. The Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1990, 323, 295-301.
5. Wong, D. K. H.; Cheung, A. M.; O'Rourke, K.; Naylor, C. D.; Detsky, A. S.; Heathcote, J. Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen- Positive Chronic Hepatitis B. A Meta-Analysis. Ann. Intern. Med. 1993, 119, 312-323.
6. Torresi, J.; Locarnini, S. Antiviral Chemotherapy for the Treatment of Hepatitis B Virus Infections. Gastroenterologe 2000, 118 (Suppl. 2), 83-103.
7. Dunkle, F. M. Frontiers in Drug Development for Viral Hepatitis. ID Weekly Highlights. Curr. Drugs 2002, Jan., 30-32.
8. Farrell, G. C. Clinical Potential of Emerging New Agents in Hepatitis B. Drugs 2000, 60, 701-710.
9. Delaney, W. E.; Locarnini, S., IV; Shaw, T. Resistance of Hepatitis B Virus to Antiviral Drugs: Current Aspects and Directions for Future Investigation. Antiviral Chem. Chemother. 2001, 12, 1-35.
10. Tao, P.-Z.; Lofgren, B.; Lake-Bakaar, D.; Johansson, N. G.; Datema, R.; Oberg, B. Inhibition of Human Hepatitis B Virus DNA Polymerase and Duck Hepatitis B Virus DNA Polymerase by Tri-Phosphates of Thymidine Analogues and Pharmacokinetic Properties of the Corresponding Nucleosides. J. Med. Virol. 1988, 26, 353-362.
11. Chang, C. N.; Doong, S. L.; Zhou, J. H.; Beach, J. W.; Jeong, L. S.; Chu, C. K.; Tsai, C. H.; Cheng, Y. C.; Liotta, D.; Schinazi, R. Deoxycytidine Deaminase-resistant Stereoisomer is the Active Form of (+/-)-2′,3′- Dideoxy-3′-thiacytidine in the Inhibition of Hepatitis B Virus Replication. J. Biol. Chem. 1992, 267, 13938-13942.
12. Doong, S. L.; Tsai, C. H.; Schinazi, R. F.; Liotta, D. C.; Cheng, Y. C. Inhibition of the Replication of Hepatitis B virus In vitro by 2′,3′-Dideoxy-3′-thiacytidine and Related Analogues. Proc. Natl. Acad. Sci. U.S.A. 1991, 88, 8495-8499.
13. Severini, A.; Liu, X. Y.; Wilson, J. S.; Tyrrell, D. L. Mechanism of Inhibition of Duck Hepatitis B Virus Polymerase by (-)-beta-L-2′,3′- Dideoxy-3′-thiacytidine. Antimicrob. Agents Chemother. 1995, 39, 1430-1435.
14. Dienstag, J. L.; Schiff, E. R.; Wright, T. L.; Perrillo, R. P.; Hann, H.-W. L.; Goodman, Z.; Crowther, L. B. S.; Condreay, L. D.; Woessner, M. B. S.; Rubin, M.; Brown, N. A.; Brown, N. A. The U.S. Lamivudine Investigator Group. Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States. N. Engl. J. Med. 1999, 341, 1256-1263.
15. Lai, C. L.; Chien, R. N.; Leung, N. W.; Chang, T. T.; Guan, R.; Tai, D. I.; Ng, K. Y.; Wu, P. C.; Dent, J. C.; Barber, J.; Stephenson, S. L.; Gray, D. F. A One-year Trial of Lamivudine for Chronic Hepatitis B. Asia Hepatitis Lamivudine Study Group. N. Engl. J. Med. 1998, 339, 61-68.
16. Nicoll, A. J.; Colledge, D. L.; Toole, J. J.; Angus, P. W.; Smallwood, R. A.; Locarnini, S. A. Inhibition of Duck Hepatitis B Virus Replication by 9-(2-Phosphonylmethoxyethyl)adenine, an Acyclic Phosphonate Nucleoside Analogue. Antimicrob. Agents Chemother. 1998, 42, 3130-3135.
17. Gilson, R. J. C.; Chopra, K.; Murray, L. I. Placebo-controlled Phase I/II Study of Adefovir Dipivoxil in Patients with Chronic Hepatitis B Infection. Hepatology 1996, 24 (Suppl. 1), 281A.
18. Malik, A. H.; Lee, W. M. Chronic Hepatitis B Virus Infection: Treatment Strategies for the Next Millennium. Ann. Intern. Med. 2000, 132, 723-731.
19. Hepsera Full Prescribing Information. Gilead Sciences. 09/2002, 1-18.
20. Zoulim, F. Entecavir: A New Treatment Option for Chronic Hepatitis B. J. Clin. Virol., in press.
21. De Clercq, E. Perspectives for the Treatment of Hepatitis B Virus Infections. Int. J. Antimicrob. Agents 1999, 12, 81-95.
22. (a) Genovesi, E. V.; Lamb, L.; Medina, I.; Taylor, D.; Seifer, M.; Innaimo, S.; Colonno, R. J.; Standring, D. N.; Clark, J. M. Efficacy of the Carbocyclic 2′-Deoxyguanosine Nucleoside BMS-200475 in the Woodchuck Model of Hepatitis B Virus Infection. Antimicrob. Agents Chemother. 1998, 42, 3209-3217.
23. (b) Levine, S.; Hernaandez, D.; Yamanake, G.; Zhang, S.; Rose, R.; Weinheimer, S.; Colonno, R. J. Efficacies of Entecavir Against Lamivudine-resistant Hepatitis B Virus Replication and Recombinant Polymerases In Vitro. Antimicrob. Agents Chemother. 2002, 46, 2525-2532.
24. Tassopoulos, N.; Cianciara, J.; Rizzetto, M. Entecavir is Effective in Treating Patients with Chronic Hepatitis B Who Have Failed Lamivudine Therapy. Hepatology 2001, 34 (Pt 2), 340A.
25. Lai, C. L.; Rosmawati, M.; Lao, J.; Van Vlierberghe, H.; Anderson, F. H.; Thomas, N.; Dehertogh, D. Entecavir is Superior to Lamivudine in Reducing Hepatitis B Virus DNA in Patients with Chronic Hepatitis B Infection. Gastroenterology 2002, 123, 1831-188.
26. Nevens, F.; Main, J.; Honkoop, P.; Tyrrell, D. L.; Barber, J.; Sullivan, M. T.; Fevery, J.; DeMan, R. A.; Thomas, H. C. Lamivudine Therapy for Chronic Hepatitis B: A Six Month Randomized Dose-ranging Study. Gastroenterology 1997, 113, 1258-1263.
27. Torresi, J.; Locarnini, S. Antiviral Chemotherapy for the Treatment of Hepatitis B Virus Infections. Gastroenterology 2000, 118 (Suppl. 2), 83-103.
28. Delaney, W. E., IV; Edwards, R.; Colledge, D.; Shaw, T.; Torresi, J.; Miller, T. G.; Isom, H. C.; Bock, C. T.; Manns, M. P.; Trautwein, C.; Locarnini, S. Cross-resistance Testing of Antihepadnaviral Compounds Using Novel Recombinant Baculoviruses Which Encode Drug-Resistant Strains of Hepatitis B Virus. Antimicrob. Agents Chemother. 2001, 45, 1705-1713.
29. Moraleda, G.; Saputelli, J.; Aldrich, C. E.; Averett, D.; Condreay, L.; Mason, W. S. Lack of Effect of Antiviral Therapy in Nondividing Hepatocyte Cultures on the Closed Circular DNA of Woodchuck Hepatitis Virus. J. Virol. 1997, 71, 9392-9399.
30. Addison, W. R.; Walters, K. A.; Wong, W. W.; Wilson, J. S.; Madej, D.; Jewell, L. D.; Tyrrell, D. L. Half-life of the Duck Hepatitis B Virus Covalently Closed Circular DNA Pool in vivo Following Inhibition of Viral Replication. J. Virol. 2002, 76, 6356-6363.
31. Zhu, Y.; Yamamoto, T.; Cullen, J.; Saputelli, J.; Aldrich, C. E.; Miller, D. S.; Litwin, S.; Furman, P. A.; Jilbert, A. R.; Mason, W. S. Kinetics of Hepadnavirus Loss from the Liver During Inhibition of Viral DNA Synthesis. J. Virol. 2001, 75, 311-322.
32. Liaw, Y. F.; Chien, R. N.; Yeh, C. T.; Tsai, S. L.; Chu, C. M. Acute Exacerbation and Hepatitis B Virus Clearance After Emergence of YMDD Motif Mutation During Lamivudine Therapy. Hepatology 1999, 30, 567-572.
33. Allen, M. I.; Deslauriers, M.; Andrews, C. W.; Tipples, G. A.; Walters, K. A.; Tyrrell, D. L.; Brown, N.; Condreay, L. D. Lamivudine Clinical Investigation Group. Hepatology 1998, 27, 1670-1677.
34. Fischer, K. P.; Tyrrell, D. L. Generation of Duck Hepatitis B Virus Polymerase Mutants through Site-directed Mutagenesis which Demonstrate Resistance to Lamivudine [(-)-Beta-L-2′,3′-dideoxy-3′- thiacytidine] in vitro. Antimicrob. Agents Chemother. 1996, 40, 1957-1960.
35. Melegari, M.; Scaglioni, P. P.; Wands, J. R. Hepatitis B Virus Mutants Associated with 3TC and Famciclovir Administration are Replication Defective. Hepatology 1998, 27, 628-633.
36. Das, K.; Xiong, X.; Yang, H.; Westland, C. E.; Gibbs, C. S.; Sarafianos, S. G.; Arnold, E. Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC). J. Virol. 2001, 75, 4771-4779.
37. Minuk, G. Y.; German, G. B.; Bernstein, C.; Benarroch, A.; Gauthiar, T.; Sekla, L. A Pilot Study of Steroid Withdrawal Followed by Oral Acyclovir in the Treatment of Chronic Type B Hepatitis. Clin. Invest. Med. 1992, 15, 506-512.
38. Luscombe, C.; Pedersen, J.; Uren, E.; Locarnini, S. Long-term Ganciclovir Chemotherapy for Congenital Duck Hepatitis B Virus Infection in vivo. Effect on Intrahepatic-viral DNA, RNA, and Protein Expression. Hepatology 1996, 24, 766-773.
39. Kruining, J.; Heijtink, R. A.; Schalm, S. W. Antiviral Agents in Hepatitis B Virus Transfected Cell Lines: Inhibitory and Cytotoxic Effects Related to Time and Treatment. J. Hepatol. 1995, 22, 263-267.
40. Chachoua, A.; Dieterich, D.; Krasinski, K.; Greene, J.; Laubenstein, L.; Wernz, J.; Buhles, W.; Koretz, S. 9-(1,3-Dihydroxy-2-propoxymethyl)guanine (Ganciclovir) in the Treatment of Cytomegalovirus Gastrointestinal Disease with the Acquired Immunodeficiency Syndrome. Ann. Intern. Med. 1987, 107, 133-137.
41. Beauchamp, L. M.; Serling, B. L.; Kelsey, J. E.; Biron, K. K.; Collins, P.; Selway, J.; Lin, J.-C.; Schaeffer, H. J. Effect of Acyclic Pyrimidines Related to 9-[(1,3-Dihydroxy-2-propoxy)methyl]guanine on Herpes Viruses. J. Med. Chem. 1988, 31, 144-149.
42. Ogilvie, K. K.; Hamilton, R. G.; Gillen, M. F.; Radatus, B. K. Uracil Analogues of the Acyclonucleosides 9-[[2-Hydroxy-1-(hydroxymethyl)ethoxy]- methyl]guanine (BIOLF-62). Can. J. Chem. 1984, 62, 16-21.
43. Keppler, K.; Kiefer, G.; De Clercq, E. Synthesis and Antviral Activity of Acyclic Derivatives of 5-Ethyl-2′-deoxyuridine. Arch. Pharm. 1986, 319, 360-365.
44. Ogilvie, K. K.; Dixit, D. M. Synthesis of 5-Substituted-1-[[2-hydroxy-1- (hydroxymethyl) ethoxy]methyl]cytosines. Nucleosides Nucleotides 1983, 2, 147-154.
45. (a) Martin, J. C.; Jeffrey, G. A.; McGee, D. P.; Tippie, M. A.; Smee, D. F.; Matthews, T. R.; Verheyden, J. P. Acyclic Analogues of 2′- Deoxynucleosides Related to 9-[(1,3-Dihydroxy-2-propoxy)methyl]-guanine as Potential Antiviral Agents. J. Med. Chem. 1985, 28, 358-62.
46. (b) Chein, H. H.; Chen, Y. L.; Tzeng, C. C. Synthetic Studies on the Acyclic Nucleosides of 5-Substituted 6-Aza Uracils. Nucleosides Nucleotides 1991, 10, 1391-1406.
47. Kumar, R.; Sharma, N.; Nath, M.; Saffran, H. A.; Tyrrell, D. L. J. Synthesis and Antiviral Activity of Novel Acyclic Nucleoside Analogues of 5-(1-Azido-2-haloethyl)uracils. J. Med. Chem. 2001, 44, 4225-4229.
48. Kumar, R.; Nath, M.; Tyrrell, D. J. Design and Synthesis of Novel 5-Substituted Acyclic Pyrimidine Nucleosides as Potent and Selective Inhibitors of Hepatitis B Virus. J. Med. Chem. 2002, 45, 2032-2040.
49. Semaine, W.; Johar, M.; Tyrrell, D. L. J.; Kumar, R.; Agrawal, B. Inhibitors of Hepatitis B Virus (HBV) Replication by Pyrimidines Bearing Acyclic Moiety: Effect on Wild-type and Mutant HBV. J. Med. Chem. 2006, 49, 2049-2054.
50. Lee, B.; Luo, W.; Suzuki, S.; Robins, M. J.; Tyrrell, D. L. J. In vitro and in vivo Comparison of the Abilities of Purine and Pyrimidine 2′,3′-Dideoxynucleosides to Inhibit Duck Hepadnavirus. Antimicrob. Agents Chemother. 1989, 33, 336-339.
51. Tuttleman, J. S.; Pugh, J. C.; Summers, J. W. In vitro Experimental Infection of Primary Duck Hepatocyte Cultures with Duck Hepatitis B Virus. J. Virol. 1986, 58, 17-25.
52. Walters, K. A.; Tipples, G. A.; Allen, M. I.; Condreay, L. D.; Addison, W. R.; Tyrrell, L. Generation of Stable Cell Lines Expressing Lamivudine-Resistant Hepatitis B Virus for Antiviral-Compound Screening. Antimicrob. Agents Chemother. 2003, 47, 1936-1942.
53. Shaw, T.; Amor, P.; Civitico, G.; Boyd, M.; Locarnini, S. In Vitro Antiviral Activity of Penciclovir, A Novel Purine Nucleoside, Against Duck Hepatitis B Virus. Antimicrob. Agents Chemother. 1994, 38, 719-723.
54. Kumar, R.; Tyrrell, D. J. Novel 5-Vinyl Pyrimidine Nucleosides with Potent anti-Hepatitis B Virus Activity. Bioorg. Med. Chem. Lett. 2001, 11, 2917-2920.
55. Reimer, K.; Matthes, E.; Janta-Lipinski, M. V.; Meisel, H. Inhibition of Hepatitis B Virus DNA Polymerase by Thymidine Phosphate Analogues in Vitro. Antiviral Chem. Chemother. 1991, 2, 249-253.
56. Ono, S. K.; Kato, N.; Shiratori, Y.; Kato, J.; Goto, T.; Schinazi, R. F.; Carrilho, F. J.; Omata, M. The polymerase L528M Mutation Cooperates with Nucleotide Binding-site Mutations, Increasing Hepatitis B Virus Replication and Drug Resistance. J. Clin. Invest. 2001, 107, 449-455.
57. Perrillo, R.; Schiff, E.; Yoshida, E.; Stauer, A.; Hirsch, K.; Wright, T.; Gutfreund, K.; Lamy, P.; Murray, A. Adefovir Dipivoxil for the Treatment of Lamivudine-resistant Hepatitis B Mutants. Hepatology 2000, 32, 129-134.
58. Bartholomew, M. M.; Jansen, R. W.; Jeffers, L. J.; Reddy, K. R.; Johnson, L. C.; Bunzendahl, H.; Condreay, L. D.; Tzakis, A. G.; Schiff, E. R.; Brown, N. A. Hepatitis-B-Virus Resistance to Lamivudine Given for Recurrent Infection after Orthotopic Liver Transplantation. Lancet 1997, 349, 20-22.
59. Korba, B. E.; Boyd, M. R. Penciclovir is a Selective Inhibitor of Hepatitis B Virus Replication in Cultured Human Hepatoblastoma Cells. Antimicrob. Agents Chemother. 1996, 40, 1282-1284.
60. Sells, M. A.; Chen, M. L.; Acs, M. L. Production of Hepatitis B Virus Particles in Hep G2 Cells Transfected with Cloned Hepatitis B Virus DNA. Proc. Natl. Acad. Sci. U.S.A. 1987, 84, 1005-1009.